Literature DB >> 26537748

Immune-checkpoint blockade: the springboard for immuno-combination therapy.

A M Ibrahim1, Y Wang1, N R Lemoine1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26537748     DOI： 10.1038/gt.2015.98

Source DB:  PubMed          Journal:  Gene Ther        ISSN： 0969-7128            Impact factor:   5.250


× No keyword cloud information.
  10 in total

Review 1.  The future of immune checkpoint therapy.

Authors:  Padmanee Sharma; James P Allison
Journal:  Science       Date:  2015-04-03       Impact factor: 47.728

Review 2.  From virotherapy to oncolytic immunotherapy: where are we now?

Authors:  Robert S Coffin
Journal:  Curr Opin Virol       Date:  2015-06-26       Impact factor: 7.090

3.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

Review 4.  Immune checkpoint modulation: rational design of combination strategies.

Authors:  Dmitriy Zamarin; Michael A Postow
Journal:  Pharmacol Ther       Date:  2015-01-10       Impact factor: 12.310

Review 5.  Combining immunotherapy and targeted therapies in cancer treatment.

Authors:  Matthew Vanneman; Glenn Dranoff
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

6.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Authors:  Philip W Kantoff; Celestia S Higano; Neal D Shore; E Roy Berger; Eric J Small; David F Penson; Charles H Redfern; Anna C Ferrari; Robert Dreicer; Robert B Sims; Yi Xu; Mark W Frohlich; Paul F Schellhammer
Journal:  N Engl J Med       Date:  2010-07-29       Impact factor: 91.245

Review 7.  Going viral with cancer immunotherapy.

Authors:  Brian D Lichty; Caroline J Breitbach; David F Stojdl; John C Bell
Journal:  Nat Rev Cancer       Date:  2014-07-03       Impact factor: 60.716

Review 8.  Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.

Authors:  O J Finn
Journal:  Ann Oncol       Date:  2012-09       Impact factor: 32.976

9.  Enhancement of antitumor immunity by CTLA-4 blockade.

Authors:  D R Leach; M F Krummel; J P Allison
Journal:  Science       Date:  1996-03-22       Impact factor: 47.728

10.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.

Authors:  E A Tivol; F Borriello; A N Schweitzer; W P Lynch; J A Bluestone; A H Sharpe
Journal:  Immunity       Date:  1995-11       Impact factor: 31.745
  10 in total
  1 in total

1.  Immuno-oncology combinations: raising the tail of the survival curve.

Authors:  Samuel J Harris; Jessica Brown; Juanita Lopez; Timothy A Yap
Journal:  Cancer Biol Med       Date:  2016-06       Impact factor: 4.248
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.